MedTrace Logo

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

NCT06663098 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2025-03-13

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if a combination of atezolizumab and standard chemotherapy works to treat sensitive Extensive-stage Small Cell Lung Cancer, progressing after first-line of treatment.

The main questions it aims to answer are:

* Does combination of atezolizumab and standard chemotherapy increase overall survival?
* What medical problems do participants have when taking combination of atezolizumab and standard chemotherapy?

Participants will:

* take atezolizumab and standard chemotherapy every 3 weeks for 4 cycles and than atezolizumab every 3 weeks up to 18 cycles.
* visit the clinic once every 3 weeks for checkups and tests
* perform Radiological assessments after 6 weeks and then every 12 weeks to determine response to treatment.

Conditions

  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG

Atezolizumab

1200 mg IV on day 1 of every 21 days, during induction phase and maintenance phase

DRUG

Carboplatin

AUC 4 or 5, depending on patient's characteristics, on day 1 every 21 days during induction phase

DRUG

Etoposide

80 mg/sqm or 100 mg/sqm, depending on patient's characteristics, on days 1-2-3 of every 21 days

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Gruppo Oncologico Italiano di Ricerca Clinica

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-24
Primary Completion
2028-08-30
Completion
2029-06-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06663098 on ClinicalTrials.gov